www.tonixpharma.com Open in urlscan Pro
162.241.142.33  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content

 * About
   * Leadership
     * Executive Team
     * Board of Directors
   * Facilities
 * Therapeutic Areas Overview
   * Central Nervous System
     * Fibromyalgia
     * Posttraumatic Stress Disorder
     * Long COVID
     * Cocaine Intoxication
     * Migraine
     * Depression
   * Immunology
     * Organ Transplant Rejection
     * Gastro-Intestinal Cancers
   * Infectious Disease
     * Monkeypox
     * Smallpox
     * COVID-19
   * Rare Disease
     * Prader-Willi Syndrome
 * Pipeline
   * Central Nervous System
     * TNX-102 SL
     * TNX-601 ER
     * TNX-1300
     * TNX-1900
   * Immunology
     * TNX-1500
     * TNX-1700
   * Infectious Disease
     * TNX-801
     * TNX-1850
   * Rare Disease
     * TNX-2900
   * Scientific Presentations
   * Expanded Access Policy
 * Medicines
 * Clinical Trials
 * News & Events
   * Tonix in the News
   * Press Releases
   * Investor Presentations
   * IR Events
   * Op-eds
 * Investors
   * News & Events
   * Presentations
   * Multimedia
   * Financial Info
   * Stock Data
   * SEC Filings
   * Governance
 * Careers
 * Contact Us

TONIX IS ENROLLING IN A PHASE 3 STUDY FOR FIBROMYALGIA, AND A PHASE 2 STUDY FOR
MAJOR DEPRESSIVE DISORDER. PLEASE VISIT CLINICAL TRIALS.

Slide



Slide





OUR MISSION, VISION, AND CORE VALUES

OUR MISSION IS TO IMPROVE POPULATION HEALTH BY INVENTING AND DEVELOPING
INNOVATIVE THERAPIES AND VACCINES, THROUGH BROAD IN-HOUSE CAPABILITIES AND
CREATIVE COLLABORATIONS, TO HELP ADDRESS IMPORTANT UNMET NEEDS. WE STRIVE TO DO
THIS BY USING OUR INTEGRATED DEVELOPMENT ENGINE TO ADVANCE INNOVATIVE PROGRAMS
ACROSS MULTIPLE THERAPEUTIC AREAS INTO THE CLINIC WHILE MAXIMIZING ASSET
POTENTIAL.

OUR VISION IS TO BE A LEADER IN PROVIDING NOVEL DRUG THERAPIES AND VACCINES TO
IMPROVE POPULATION HEALTH AROUND THE WORLD.

OUR CORE VALUES REFLECT OUR PRINCIPLES AND DEFINE OUR CULTURE AS WE STRIVE TO
SUCCEED IN OUR MISSION AND VISION.



TO LEARN MORE ABOUT US, VIEW OUR VIDEO.




OUR MISSION, VISION, AND CORE VALUES

OUR MISSION IS TO IMPROVE POPULATION HEALTH BY INVENTING AND DEVELOPING
INNOVATIVE THERAPIES AND VACCINES, THROUGH BROAD IN-HOUSE CAPABILITIES AND
CREATIVE COLLABORATIONS, TO HELP ADDRESS IMPORTANT UNMET NEEDS. WE STRIVE TO DO
THIS BY USING OUR INTEGRATED DEVELOPMENT ENGINE TO ADVANCE INNOVATIVE PROGRAMS
ACROSS MULTIPLE THERAPEUTIC AREAS INTO THE CLINIC WHILE MAXIMIZING ASSET
POTENTIAL.

OUR VISION IS TO BE A LEADER IN PROVIDING NOVEL DRUG THERAPIES AND VACCINES TO
IMPROVE POPULATION HEALTH AROUND THE WORLD.

OUR CORE VALUES REFLECT OUR PRINCIPLES AND DEFINE OUR CULTURE AS WE STRIVE TO
SUCCEED IN OUR MISSION AND VISION.



TO LEARN MORE ABOUT US, VIEW OUR VIDEO.




LATEST NEWS

July 17, 2023

Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase
2 Trial with the University of Washington to Study TNX-1900 (Potentiated
Intranasal Oxytocin) for Social Anxiety Disorder

July 10, 2023

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2
‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of
Pediatric Obesity

July 6, 2023

Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the
U.S. National Academies

July 3, 2023

Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed
Migraine Products




ABOUT TONIX PHARMACEUTICALS

Tonix has a robust pipeline of programs in development stages ranging from
preclinical to mid-Phase 3, across multiple therapeutic modalities, employing
varied routes of administration. Tonix’s pipeline is managed by a team of
passionate professionals that are adept at advancing innovative programs into
the clinic.

While many of Tonix’s product candidates are proprietary, in-house developments,
it also has collaborations with world-class academic and non-profit research
organizations as well as license agreements with other biotech companies.


LEARN MORE ABOUT US




THERAPEUTIC AREAS

Central Nervous System

Tonix is dedicated to finding cures for difficult to treat, widely occurring,
chronic disorders of the central nervous system including pain, neurological,
psychiatric and addiction conditions.* Our goal is to heal sufferings of
millions through scientific advancements.

Immunology

We are advancing scientific programs that focus on therapeutics to prevent organ
transplant rejection, to manage autoimmune conditions, and to improve responses
to immunotherapy in certain cancers.*

Infectious Disease

Tonix’s infectious disease portfolio targets pathogenic infections, including
monkeypox and smallpox for biodefense. Through its live virus vaccine platform
and in-house capabilities, Tonix strives to be prepared for future pandemics.

Rare Disease

Tonix is committed to improving patient care, including for those suffering from
rare diseases and for which no drug has been approved. Rare diseases are often
caused by genetic disorders and are characterized by complex symptoms. A rare
disease is a condition that affects fewer than 200,000 people in the US as
defined in the Orphan Drug Act of 1983.

CENTRAL NERVOUS SYSTEM

Tonix is dedicated to finding cures for difficult to treat, widely occurring,
chronic disorders of the central nervous system including pain, neurological,
psychiatric and addiction conditions.* Our goal is to heal sufferings of
millions through scientific advancements.

LEARN MORE

IMMUNOLOGY

We are advancing scientific programs that focus on therapeutics to prevent organ
transplant rejection, to manage autoimmune conditions, and to improve responses
to immunotherapy in certain cancers.*

LEARN MORE

INFECTIOUS DISEASE

Tonix’s infectious disease portfolio targets pathogenic infections, including
the ongoing COVID-19 pandemic. Tonix is attacking COVID-19 using vaccines,
antivirals and a Long COVID therapeutic.* Pandemic preparedness is necessary to
combat infections like SARS-CoV-2.

LEARN MORE

RARE DISEASE

Tonix is committed to improving patient care, including for those suffering from
rare diseases and for which no drug has been approved. Rare diseases are often
caused by genetic disorders and are characterized by complex symptoms. A rare
disease is a condition that affects fewer than 200,000 people in the US as
defined in the Orphan Drug Act of 1983.

LEARN MORE



PIPELINE HIGHLIGHTS

Using our integrated clinical development engine, we advance innovative programs
into the clinic while maximizing asset potential.

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Mid-Phase III — RESILIENT study enrolling

Mid-Phase III

TNX-1300   Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation

Mid-Phase II

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I start — targeting 3Q 2023

Preclinical

VIEW OUR COMPLETE PIPELINE



MANAGEMENT TEAM

“Many frontiers remain in the fields of medical science and drug development. At
Tonix, we have carefully chosen pursuits in immunology, rare diseases,
infectious diseases, and central nervous system disorders. We are building
capabilities in synthetic biology, precision medicine, protein engineering, and
vaccine manufacturing to develop better and safer medicines. Our ultimate goals
are to improve and extend the lives of millions of people and, importantly, to
reward the dedication and commitment of our stakeholders.”
— Dr. Seth Lederman, M.D., President and CEO, Tonix Pharmaceuticals

MEET OUR TEAM


*ALL OF TONIX’S PRODUCT CANDIDATES ARE INVESTIGATIONAL NEW DRUGS OR BIOLOGICS
AND HAVE NOT BEEN APPROVED FOR ANY INDICATION.


Sign up for Email Alerts

 * Contact Us
 * Privacy Policy
 * Terms of Use
 * Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.

Cookie Notification
We use 1st and 3rd party cookies to enhance your experience of our website, save
your preferences, and provide us with information on how you use our website.
For more information, please refer to our Privacy Policy. By accessing or using
our website, you consent to our use of cookies. You may opt out of the use of
cookies by adjusting your browser settings.

Accept